|
LUNG CANCER, SUSCEPTIBILITY TO
|
|
0.700 |
SusceptibilityMutation
|
CLINVAR |
|
|
|
|
Rheumatoid Arthritis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Fas (rs1800682) and FasL (rs763110) polymorphism were associated with the risk of IVDD and Fas (rs2234767) was correlated to the susceptibility of OA and RA.
|
29734947 |
2018 |
|
Rheumatoid Arthritis
|
|
0.020 |
GeneticVariation
|
BEFREE |
In conclusion, this study demonstrated that Fas rs2234767 G/A and Bcl2 rs17757541 T/C polymorphisms might be associated with an increased risk of RA.
|
26905515 |
2016 |
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Studies on the association between the FAS/FASL polymorphisms (FAS-1377G/A rs2234767, FAS-670A/G rs1800682, and FASL-844C/T rs763110) and breast cancer risk have reported inconsistent results.
|
24248546 |
2014 |
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
Studies on the association between the FAS/FASL polymorphisms (FAS-1377G/A rs2234767, FAS-670A/G rs1800682, and FASL-844C/T rs763110) and breast cancer risk have reported inconsistent results.
|
24248546 |
2014 |
|
Malignant Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
Further studies on a larger sample size and considering gene-environment interactions should be conducted to confirm the role of FAS polymorphisms, especially rs2234767G/A, in cancer risk.
|
24568648 |
2014 |
|
Malignant Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
We found that the rs2234767 G-allele was a protective factor for cancer risk (GG vs. AA: OR=0.88, 95% CI=0.79-0.98; GG+GA vs. AA: OR=0.87, 95% CI=0.79-0.96).
|
24568648 |
2014 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
Further studies on a larger sample size and considering gene-environment interactions should be conducted to confirm the role of FAS polymorphisms, especially rs2234767G/A, in cancer risk.
|
24568648 |
2014 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
We found that the rs2234767 G-allele was a protective factor for cancer risk (GG vs. AA: OR=0.88, 95% CI=0.79-0.98; GG+GA vs. AA: OR=0.87, 95% CI=0.79-0.96).
|
24568648 |
2014 |
|
Malignant Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
FAS-1377 G/A (rs2234767) polymorphism and cancer susceptibility: a meta-analysis of 17,858 cases and 24,311 controls.
|
24014103 |
2013 |
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
In conclusion, FAS rs2234767 was not associated with breast cancer risk.
|
23326385 |
2013 |
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
In conclusion, FAS rs2234767 was not associated with breast cancer risk.
|
23326385 |
2013 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
FAS-1377 G/A (rs2234767) polymorphism and cancer susceptibility: a meta-analysis of 17,858 cases and 24,311 controls.
|
24014103 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.020 |
GeneticVariation
|
BEFREE |
We investigated a common G > A polymorphism at position -1377 (rs2234767) in the core promoter of the CD95 cell death receptor gene in 708 subjects with acute myeloid leukemia, including 231 patients with APL.
|
22084312 |
2012 |
|
Leukemia, Myelocytic, Acute
|
|
0.020 |
GeneticVariation
|
BEFREE |
Fas−1377G>A (rs2234767), −670T>C (rs1800682), and FasL−844T>C (rs763110) polymorphisms in 592 AML patients and 858 healthy controls were genotyped and tested for associations between polymorphisms and AML risk.
|
20438363 |
2010 |
|
Intervertebral Disc Degeneration
|
|
0.010 |
GeneticVariation
|
BEFREE |
Fas (rs1800682) and FasL (rs763110) polymorphism were associated with the risk of IVDD and Fas (rs2234767) was correlated to the susceptibility of OA and RA.
|
29734947 |
2018 |
|
Degenerative polyarthritis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Fas (rs1800682) and FasL (rs763110) polymorphism were associated with the risk of IVDD and Fas (rs2234767) was correlated to the susceptibility of OA and RA.
|
29734947 |
2018 |
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
However, we did not observe any association between the cervical cancer risk and the rs2234767 and rs1800682 polymorphisms.
|
27790710 |
2017 |
|
Nodular Goiter
|
|
0.010 |
GeneticVariation
|
BEFREE |
Association of the blood serum cytokines' rate and lymphocytes' apoptosis with polymorphic variants of the BCL-2 (rs17759659), CTLA-4 (rs231775) and APO-1÷FAS (rs2234767) genes in patients with nodular goiters in autoimmune thyroiditis and thyroid adenoma.
|
29250672 |
2017 |
|
Thyroid Gland Follicular Adenoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Association of the blood serum cytokines' rate and lymphocytes' apoptosis with polymorphic variants of the BCL-2 (rs17759659), CTLA-4 (rs231775) and APO-1÷FAS (rs2234767) genes in patients with nodular goiters in autoimmune thyroiditis and thyroid adenoma.
|
29250672 |
2017 |
|
Hashimoto Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Association of the blood serum cytokines' rate and lymphocytes' apoptosis with polymorphic variants of the BCL-2 (rs17759659), CTLA-4 (rs231775) and APO-1÷FAS (rs2234767) genes in patients with nodular goiters in autoimmune thyroiditis and thyroid adenoma.
|
29250672 |
2017 |
|
Autoimmune thyroiditis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Association of the blood serum cytokines' rate and lymphocytes' apoptosis with polymorphic variants of the BCL-2 (rs17759659), CTLA-4 (rs231775) and APO-1÷FAS (rs2234767) genes in patients with nodular goiters in autoimmune thyroiditis and thyroid adenoma.
|
29250672 |
2017 |
|
Cervix carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
However, we did not observe any association between the cervical cancer risk and the rs2234767 and rs1800682 polymorphisms.
|
27790710 |
2017 |
|
Malignant tumor of cervix
|
|
0.010 |
GeneticVariation
|
BEFREE |
However, we did not observe any association between the cervical cancer risk and the rs2234767 and rs1800682 polymorphisms.
|
27790710 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.010 |
GeneticVariation
|
BEFREE |
FAS rs2234767 and rs1800682 polymorphisms jointly contributed to risk of colorectal cancer by affecting SP1/STAT1 complex recruitment to chromatin.
|
26759270 |
2016 |